Over time, studies of individuals diagnosed with MASLD have shown evidence of an association between GDF15 serum levels and the presence and severity of MASLD, also providing an optimal threshold of circulating GDF15 for predicting advanced fibrosis [10,17,18]. This evidence concerns the gene GDF15 and metabolic dysfunction-associated steatotic liver disease.